BOIRON |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 33.75 EUR | -1.60% |
|
-0.15% | -16.09% |
| 02-02 | Boiron: nearly 600,000 shares tendered to the OPAS | CF |
| 01-11 | Boiron: OPAS open from January 11 to 31 | CF |
| Sales 2023 | 493M 527M 42.23B | Sales 2024 * | 508M 543M 43.5B | Capitalization | 586M 627M 50.17B |
|---|---|---|---|---|---|
| Net income 2023 | 35M 37.42M 3B | Net income 2024 * | 37M 39.56M 3.17B | EV / Sales 2023 | 1.42 x |
| Net cash position 2023 * | 280M 300M 24B | Net cash position 2024 * | 121M 129M 10.36B | EV / Sales 2024 * | 0.92 x |
| P/E ratio 2023 * |
14.2
x | P/E ratio 2024 * |
15.6
x | Employees | 2,813 |
| Yield 2023 * |
3.01% | Yield 2024 * |
2.9% | Free-Float | 12.92% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -1.60% | ||
| 1 week | -0.15% | ||
| Current month | +0.39% | ||
| 1 month | +2.21% | ||
| 3 months | -18.00% | ||
| 6 months | -15.31% | ||
| Current year | -16.09% |
1 week
33.55
34.70
1 month
33.2036.00
Current year
32.4842.80
1 year
32.4856.50
3 years
32.4856.50
5 years
26.7556.50
10 years
26.75112.80
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 55 | 30/06/11 | |
Thierry Boiron
CHM | Chairman | 63 | 17/09/96 |
Frédéric Riou
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 80 | 21/05/03 | |
Thierry Boiron
CHM | Chairman | 63 | 17/09/96 |
Philippe Brun
BRD | Director/Board Member | 64 | 26/05/21 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 10 M€ | -3.35% | - | |
| 0.00% | 773 M€ | -.--% | - | |
| 0.00% | 34 M€ | +2.14% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 33.75 | -1.60% | 6,557 |
| 25/04/24 | 34.3 | +0.88% | 2,013 |
| 24/04/24 | 34 | -0.15% | 1,308 |
| 23/04/24 | 34.05 | +0.59% | 1,189 |
| 22/04/24 | 33.85 | +0.15% | 2,206 |
Real-time Euronext Paris, April 26, 2024 at 04:35 pm
More quotes
Laboratoires BOIRON was founded in France almost a century ago, under the impetus of homeopathic doctors who wanted to benefit from the most reliable medicines possible. Homeopathic medicines have many advantages in that they can be prescribed and advised in first line whenever relevant, in both urban and hospital settings. All actions aim to contribute to major public health issues.
Homeopathic medicines are obtained from substances called homeopathic strains, according to a manufacturing process described in the pharmacopoeia. These strains can be of plant, animal, mineral or chemical origin.
There are two main families of homeopathic medicines: common name homeopathic medicines and brand name homeopathic medicines (specialties).
BOIRON group centralizes its production and logistics in France. It also has 26 wholly-owned or leased distribution facilities in France and various offices in the countries where it has subsidiaries.
Net sales are distributed geographically as follows: France (52.4%), Europe (22.5%), North America (22.6%) and other (2.5%).
Sector
Pharmaceuticals
Calendar
22/05/2024
- Shareholders Meeting
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
33.75
EUR
Average target price
39.6
EUR
Spread / Average Target
+17.33%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -16.09% | 626M | |
| -15.13% | 4.51B | |
| -9.75% | 3.15B | |
| +2.14% | 3.1B | |
| -6.82% | 2.42B | |
| +47.87% | 1.97B | |
| +0.09% | 1.65B | |
| -7.89% | 1.68B | |
| -12.97% | 1.53B | |
| +33.40% | 1.38B |
- Stock Market
- Equities
- BOI Stock
